These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38761424)

  • 1. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.
    Yu L; Gao F; Li Y; Su D; Han L; Li Y; Zhang X; Feng Z
    Biomed Pharmacother; 2024 Jun; 175():116724. PubMed ID: 38761424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pattern-recognition receptors in endometriosis: A narrative review.
    Guo B; Chen JH; Zhang JH; Fang Y; Liu XJ; Zhang J; Zhu HQ; Zhan L
    Front Immunol; 2023; 14():1161606. PubMed ID: 37033937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases.
    Wicherska-Pawłowska K; Wróbel T; Rybka J
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate Immunity Crosstalk with
    Cheok YY; Tan GMY; Lee CYQ; Abdullah S; Looi CY; Wong WF
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886908
    [No Abstract]   [Full Text] [Related]  

  • 5. NOD-like receptors in the pathogenesis of metabolic (dysfunction)-associated fatty liver disease: Therapeutic agents targeting NOD-like receptors.
    Khanmohammadi S; Ramos-Molina B; Kuchay MS
    Diabetes Metab Syndr; 2023 Jul; 17(7):102788. PubMed ID: 37302383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate Immunity and MASLD.
    Meyer M; Schwärzler J; Jukic A; Tilg H
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of immune dysregulation in MASLD.
    Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
    Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-Induced Fatty Liver Disease (DIFLD): A Comprehensive Analysis of Clinical, Biochemical, and Histopathological Data for Mechanisms Identification and Consistency with Current Adverse Outcome Pathways.
    López-Pascual E; Rienda I; Perez-Rojas J; Rapisarda A; Garcia-Llorens G; Jover R; Castell JV
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern Recognition Receptors in Multiple Sclerosis and Its Animal Models.
    Deerhake ME; Biswas DD; Barclay WE; Shinohara ML
    Front Immunol; 2019; 10():2644. PubMed ID: 31781124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate and intrinsic antiviral immunity in skin.
    Kawamura T; Ogawa Y; Aoki R; Shimada S
    J Dermatol Sci; 2014 Sep; 75(3):159-66. PubMed ID: 24928148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern recognition receptors and central nervous system repair.
    Kigerl KA; de Rivero Vaccari JP; Dietrich WD; Popovich PG; Keane RW
    Exp Neurol; 2014 Aug; 258():5-16. PubMed ID: 25017883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
    Cui J; Chen Y; Wang HY; Wang RF
    Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.